StockData

Arrowhead Pharmaceuticals vs Mirum Pharmaceuticals

ARWR and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARWR and MIRM compare

Arrowhead Pharmaceuticals and Mirum Pharmaceuticals are about the same size, with market caps of $6.1B and $6.0B.

Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 16.8% for Arrowhead Pharmaceuticals).

Arrowhead Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −139% at Mirum Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARWRMIRM
Size and price
Market cap$6.1B$6.0B
Share price$42.99$91.95
Change, 1 year4.2%28.7%
Change, 5 years−40.3%586%
Beta (5Y)1.570.61
Employees711372
StockData Score
Total score55
Valuation score00
Growth score23 (better)
Performance score2 (better)1
Health score11
Dividend score00
Valuation
P/S9.1× (better)9.7×
P/B13.0×–
FCF yield−1.2% (better)−3.8%
Fair value$31.89–
Margin of safety−34.8%–
Growth
Revenue growth (TTM)16.8%44.0% (better)
Revenue growth, 5Y average56.6%–
Profitability
Operating margin−33.8% (better)−135%
Net margin−47.8% (better)−139%
FCF margin−11.2% (better)−37.0%
Return on equity−64.8% (better)−703%
Financial health
Interest coverage−2.4× (better)−62.1×
Current ratio5.90 (better)2.86
Altman Z-score1.69 (better)−0.22
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.6%110%
Held by insiders4.0%9.2%
Insider net buying, 12 months−$36.9M−$32.8M (better)
Short interest, % of float8.5%11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.